establishment of of a a rational rational relationship between between

Size: px
Start display at page:

Download "establishment of of a a rational rational relationship between between"

Transcription

1 IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA Definicija po po USP: USP: The The term term in in vitro vitro -- in in vivo vivo correlation refers refers to to the the establishment of of a a rational rational relationship between between a a biological property, or or a a parameter derived derived from from a a biological property produced by by a a dosage dosage form, form, and and a a physicochemical property or or characteristic of of the the same same dosage dosage form. form. IN IN VITRO VITRO TESTI TESTI PO PO USP USP <701> <701> DISINTEGRATION <711> <711> DISSOLUTION APARATURE aparatura 1 aparatura 2 aparatura 3 aparatura 4 POSTOPKI immediate release release dosage dosage forms forms extended release release dosage dosage forms forms delayed delayed release release dosage dosage forms: forms: metodi metodi A in in B INTERPRETACIJA <724> <724> DRUG DRUG RELEASE Aparati, Aparati, predpisani v monografijah Transdermalni sistemi sistemi aparati aparati 5, 5, 6, 6, 7 1

2 2

3 USP31 3

4 USP31 USP31 4

5 USP31 <1088> <1088> IN IN VITRO VITRO AND AND IN IN VIVO VIVO EVALUATION OF OF DOSAGE FORMS IN IN VITRO VITRO (raztapljanje/sproščanje razvoj razvoj metod) metod) Oblike Oblike s s takojšnjim sproščanjem testiranje sproščanja zahtevano za za vse vse trdne trdne oblike, oblike, pri pri katerih katerih je je za za dosego dosego učinka učinka potrebna absorpcija. Izjeme! Izjeme! Oblike Oblike s s prirejenim sproščanjem testiranje sproščanja zahtevano za za vse vse sisteme, sisteme, pri pri katerih katerih je je za za dosego dosego učinka učinka potrebna absorpcija IN IN VIVO VIVO (SISTEMI S PRIREJENIM SPROŠČANJEM) karakterizacija učinkovine fizikalno kemijske lastnosti lastnosti farmakokinetične lastnosti lastnosti disposition properties farmakodinamične lastnosti lastnosti karakterizacija oblike oblike fizikalno kemijske lastnosti lastnosti farmakokinetične lastnosti lastnosti IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA oblike oblike s s prirejenim sproščanjem oblike oblike s s takojšnjim sproščanjem 5

6 NALOGA: V KATERIH OD OD NASLEDNJIH PRIMEROV LAHKO PRIČAKUJEMO DOBRO IN IN VITRO VITRO IN IN VIVO VIVO KORELACIJO? A) A) Učinkovina se se absorbira z z aktivnim transportom B) B) Učinkovina se se sprošča sprošča enakomerno 8 ur ur in in absorbira vzdolž vzdolžcelotnega jejunuma (ne (ne v želodcu, ne ne v ileumu ileumu in in kolonu) kolonu) C) C) Sproščanje poteka poteka z z enakomerno hitrostjo mmol/h, absorpcija pa pa s s hitrostjo 2 2 mmol/h D) D) Sproščanje poteka poteka z z enakomerno hitrostjo 2 2 mmol/h, absorpcija pa pa s s hitrostjo mmol/h IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA Definicija po po USP: USP: The The term term in in vitro vitro -- in in vivo vivo correlation refers refers to to the the establishment of of a a rational rational relationship between between a a biological property, or or a a parameter derived derived from from a a biological property produced by by a a dosage dosage form, form, and and a a physicochemical property or or characteristic of of the the same same dosage dosage form. form. 6

7 IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA biološka lastnost: lastnost: farmakokinetičen parameter -- plazemski koncentracijski profili: profili: AUC, AUC, Cmax Cmax fizikalno kemijska lastnost: sproščanje učinkovine Nivoji Nivoji korelacije: nivo nivo A: A: najvišja najvišja stopnja stopnja korelacije point-to-point korelacija = celotni celotni profili profili nivo nivo B: B: primerjava parametrov (statističnih momentov): uporaba uporaba VSEH VSEH podatkov! MDT MDT // M(in M(in vivod)t nivo nivo C: C: primerjava v eni eni točki točki t50%, t50%, t90% t90% // AUC, AUC, tmax, tmax, Cmax Cmax Plazemski profil Profil sproščanja 7

8 Plazemski profil Absorpcijski profil Profil sproščanja Absorpcijski profil Profil sproščanja IVIVC 8

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Bryan Crist Scientific Affairs Manager, Agilent Technologies, Dissolution Systems Dissolution Exchange WebEx Bryan.crist@agilent.com August,

More information

Clinically Relevant Specifications (CRS): A Regulatory Perspective

Clinically Relevant Specifications (CRS): A Regulatory Perspective Clinically Relevant Specifications (CRS): A Regulatory Perspective Richard (Rik) Lostritto, Ph.D. Acting Deputy Director for Science & Policy and Acting Biopharmaceutics Lead, Office of New Drug Quality

More information

European Guidance on Modified Release Dosage Forms

European Guidance on Modified Release Dosage Forms Safeguarding public health European Guidance on Modified Release Dosage Forms Terry Shepard, Pharmacokinetics Assessor Medicines and Healthcare products Regulatory Agency London PQRI Workshop on Application

More information

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC Mechanistic IVIVC Using the Simcyp ADAM Model Make SCIENCE out of IVIVC %Dissolved in vivo % Dissolved/Absorbed %Dissolved/Absorbed Plasma Conc (ng/ml) IVIVC and Its Components IVIVC: A predictive mathematical

More information

Guideline on quality of oral modified release products

Guideline on quality of oral modified release products 20 March 2014 EMA/CHMP/QWP/428693/2013 Committee for Medicinal Products for Human Use (CHMP) Final Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public

More information

In Vitro-In Vivo Correlation:

In Vitro-In Vivo Correlation: In Vitro-In Vivo Correlation: Linking Drug Release to Clinical Performance Yihong Qiu, Ph.D. Abbott Laboratories 51st Land O' Lakes Conference: Bridging Material and Product Quality in Developing Tablet

More information

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997 Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products

More information

Hydrostatic Bearings for Machine Tools

Hydrostatic Bearings for Machine Tools Hydrostatic Bearings for Machine Tools Georg MÖRWALD, Jörg EDLER, Heinrich G. HOCHLEITNER Abstract: Hydrostatic bearings have advantages due to their simple design, wear-free performance and good damping

More information

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs Nikunjkumar Patel, Simcyp Limited IVIVC and Its Components CONVOLUTION VALIDATION DECONVOLUTION MODELS IVIVC

More information

Guideline on quality of oral modified release products

Guideline on quality of oral modified release products 1 2 3 23 August 2012 EMA/492713/2012 Quality Working Party (QWP) 4 5 Draft Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public consultion 15 September

More information

Injectable modified release products

Injectable modified release products Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the

More information

Application Strategy of PBPK for Generic Drugs and Its Current Challenges

Application Strategy of PBPK for Generic Drugs and Its Current Challenges BUILD A PHARMACEUTICAL COMPANY Application Strategy of PBPK for Generic Drugs and Its Current Challenges Bo Liu June 18, 2017 1 PuraCap Global Presence PuraCap Laboratories LLC, Kentucky PuraCap Pharmaceutical

More information

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

Biowaiver Approaches for Generic Drug Products in the US: Case Studies About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information

More information

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC 1. INTRODUCTION The therapeutic efficacy of pharmaceutical formulations is governed by factors related to both the in vitro dissolution characteristics

More information

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne

More information

Dissolution Apparatus Types

Dissolution Apparatus Types Dissolution Apparatus Types Thank you for reading. As you may know, people have look numerous times for their favorite books like this, but end up in infectious downloads. Rather than enjoying a good book

More information

Dissolution and clinically relevant specifications: linking clinical performance to dissolution

Dissolution and clinically relevant specifications: linking clinical performance to dissolution Dissolution and clinically relevant specifications: linking clinical performance to dissolution Talia Flanagan, Dave Holt, Paul Dickinson, Paul Stott. FDA/PQRI Conference on Evolving Product Quality 16-17

More information

Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives

Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives Quality by Design & Clinical Relevance: Moving Forward Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives Roger Nosal 1 & Ravi Shanker 2 1 Vice President & Head Global

More information

Common Deficiences in Bioequivalence Studies and Biowaiver Requests submitted to the JFDA

Common Deficiences in Bioequivalence Studies and Biowaiver Requests submitted to the JFDA Common Deficiences in Bioequivalence Studies and Biowaiver Requests submitted to the JFDA DIMA S. SHAHIN, M.SC. MEMBER OF THE BIOEQUIVALENCE STUDIES TECHNICAL COMMITTEE REGISTRATION DEPARTMENT, DRUG DIRECTORATE-

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT

More information

BCS, Biowaivers and Dissolution Test Methodologies

BCS, Biowaivers and Dissolution Test Methodologies BCS, Biowaivers and Dissolution Test Methodologies Vinod P. Shah, Ph.D., FAAPS, FFIP Pharmaceutical Consultant, (Formerly with US FDA) North Potomac, MD., USA Disso Europe 2016 Romania Advances and Applications

More information

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Nikunj Patel, Senior Research Scientist Simcyp (a Certara Company) AAPS

More information

First UNGAP meeting Food-Drug Interactions Regulatory Aspects

First UNGAP meeting Food-Drug Interactions Regulatory Aspects First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal

More information

Model based approaches to target special populations with rational formulation and clinical design strategies

Model based approaches to target special populations with rational formulation and clinical design strategies Model based approaches to target special populations with rational formulation and clinical design strategies David Good 3 rd FDA/PQRI Conference on Advancing Product Quality Modeling for Oral and Non-Oral

More information

Approach, Information needed and criteria- suggested by the members of the IQ dissolution WG

Approach, Information needed and criteria- suggested by the members of the IQ dissolution WG Framework for setting Clinically relevant Dissolution Specification (CRS) Approach, Information needed and criteria- suggested by the members of the IQ dissolution WG Andreas Abend Merck Research Labs

More information

Who we are? Dissolution testing of modified release forms. Dissolution testing of immediate/ modified release forms

Who we are? Dissolution testing of modified release forms. Dissolution testing of immediate/ modified release forms Dissolution testing of modified release forms Mumbai - 2013, May 3 Samir Haddouchi samir.haddouchi@sps-pharma.com 1 Dissolution testing of immediate/ modified release forms Mumbai - 2013, May 3 Samir Haddouchi

More information

Kvantitativna analiza in R doc. dr. Franc Brcar

Kvantitativna analiza in R doc. dr. Franc Brcar Kvantitativna analiza in R doc. dr. Franc Brcar Prirejeno po: Field, A., Miles, J., & Field, Z. (2012). Discovering Statistics Using R. London: SAGE. 1 Discovering Statistics Using R & SPSS 2 Program dela

More information

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA PQRI BTC Webinar December 06, 2018 DISCLAIMER The presentation

More information

Draft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017

Draft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017 18 October 2018 CPMP/EWP/239/95 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally

More information

NUMERICAL OPTIMIZATION OF THE METHOD OF COOLING OF A MASSIVE CASTING OF DUCTILE CAST-IRON

NUMERICAL OPTIMIZATION OF THE METHOD OF COOLING OF A MASSIVE CASTING OF DUCTILE CAST-IRON UDK 669.1:621.74 ISSN 1580-2949 Original scientific article/izvirni znanstveni ~lanek MTAEC9, 43(2)73(2009) NUMERICAL OPTIMIZATION OF THE METHOD OF COOLING OF A MASSIVE CASTING OF DUCTILE CAST-IRON NUMERI^NA

More information

Overview of comments received on 'guideline on quality of oral modified release products' (EMA/CHMP/QWP/428693/2013)

Overview of comments received on 'guideline on quality of oral modified release products' (EMA/CHMP/QWP/428693/2013) 20 March 2014 EMA/CHMP/QWP/428694/2013 Committee for Human Medicinal Products (CHMP) Overview of comments received on 'guideline on quality of oral modified release products' (EMA/CHMP/QWP/428693/2013)

More information

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity

More information

Case Study: Merck & Co., Inc.

Case Study: Merck & Co., Inc. Case Study: Merck & Co., Inc. Use of In Vivo Pharmacokinetic Data to Develop a CRS for In Vitro Dissolution Testing Barbara M. Davit Merck & Co., Inc. ( Merck ) UMD/FDA CERSI Workshop May 17, 2017 Implementing

More information

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October

More information

QbD and Applied Biopharmaceutics for Patient Benefit

QbD and Applied Biopharmaceutics for Patient Benefit QbD and Applied Biopharmaceutics for Patient Benefit Arzu Selen, Ph.D. Associate Director, Biopharmaceutics Office of New Drug Quality Assessment/CDER/FDA The 32 nd Annual Midwest Biopharmaceutical Statistics

More information

Role of PBPK based virtual trials modeling in generic product development and regulation

Role of PBPK based virtual trials modeling in generic product development and regulation Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation

More information

IVIVC approach based on carbamazepine bioequivalence studies combination

IVIVC approach based on carbamazepine bioequivalence studies combination Department of Pharmaceutics and Pharmaceutical Technology 1, University of Valencia; Department of Engineering 2, Area of Pharmaceutics and Pharmaceutical Technology, University Miguel Hernández, Elche;

More information

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00.

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00. Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS Course Code CT113 Lecture : 05 Course Credit Practical : 04 Tutorial : 00 Total : 09 Course Objectives Upon completion of course

More information

USP s Perspective on Drug Product Performance Test

USP s Perspective on Drug Product Performance Test USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development

More information

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

Cocrystals: A Regulatory Perspective. Scott L. Childs Renovo Research

Cocrystals: A Regulatory Perspective. Scott L. Childs Renovo Research Cocrystals: A Regulatory Perspective Scott L. Childs Renovo Research Outline FDA guidance EMA reflection paper Global regulatory strategies Potential for commercial impact Summary of FDA Guidance Cocrystals

More information

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

Guideline for the quality, safety and efficacy of follow-on biological medicinal products Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a

More information

Formulation Considerations for Over-Encapsulation of Clinical Trial Materials in DBcaps Capsules. Samantha Lai, Ph.D.

Formulation Considerations for Over-Encapsulation of Clinical Trial Materials in DBcaps Capsules. Samantha Lai, Ph.D. Formulation Considerations for Over-Encapsulation of Clinical Trial Materials in DBcaps Capsules Samantha Lai, Ph.D. BAS 251 E 2003 DBcaps capsules are often specified for over-encapsulation of active

More information

Dissolution Testing. Development / Quality Control and in vivo Relevance. 31 May 1 June 2017 Copenhagen, Denmark HIGHLIGHTS:

Dissolution Testing. Development / Quality Control and in vivo Relevance. 31 May 1 June 2017 Copenhagen, Denmark HIGHLIGHTS: Dissolution Testing Development / Quality Control and in vivo Relevance SPEAKERS DR THOMAS FÜRST Boehringer Ingelheim DR KERSTIN PAULI Bayer AG Image: ERWEKA GmbH, Germany DR ALEXANDER PONTIUS Bayer AG

More information

In vivo predictive biopharmaceutics tools for oral drug delivery

In vivo predictive biopharmaceutics tools for oral drug delivery In vivo predictive biopharmaceutics tools for oral drug delivery Bertil Abrahamsson, AstraZeneca and Mark McAllister, Pfizer Background non-absorbable drug complex complex formation drug in solid dosage

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

BCS Guidance and Biowaivers BCS Monographs

BCS Guidance and Biowaivers BCS Monographs BCS Guidance and Biowaivers BCS Monographs Vinod P. Shah, Ph.D., Pharmaceutical Consultant PQRI Board Member 2 nd FDA/PQRI Conference on Advancing Product Quality Emerging Regulatory Initiatives Biopharmaceutics

More information

Dissolution Testing Development / Quality Control and in vivo Relevance

Dissolution Testing Development / Quality Control and in vivo Relevance Dissolution Testing Development / Quality Control and in vivo Relevance SPEAKERS DR KERSTIN PAULI Bayer AG DR ALEXANDER PONTIUS Bayer AG Image: ERWEKA GmbH, Germany DR JOCHEN SCHER Boehringer Ingelheim

More information

QbD implementation in Generic Industry: Overview and Case-Study

QbD implementation in Generic Industry: Overview and Case-Study QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They

More information

Professor Andrea Laslop, MD, Austria

Professor Andrea Laslop, MD, Austria GaBI Scientific Meetings ROUNDTABLE ON BIOSIMILARS with participation by European Regulators and Medical Societies 12 January 2016, Sheraton Brussels Airport Hotel, Belgium Professor Andrea Laslop, MD,

More information

The role and future of dissolution testing in a QBD product development framework

The role and future of dissolution testing in a QBD product development framework The role and future of dissolution testing in a QBD product development framework Paul Dickinson, AstraZeneca, Alderley Park, Cheshire Senior Clinical Pharmacology Scientist paul.dickinson@astrazeneca.com

More information

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

NOT FOR IMPLEMENTATION GUIDANCE FOR INDUSTRY "NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo

More information

US FDAs Perspective on Product Quality and Bioequivalence

US FDAs Perspective on Product Quality and Bioequivalence US FDAs Perspective on Product Quality and Bioequivalence Vinod P. Shah, Ph. D. Pharmaceutical Consultant (Formerly with US FDA) Scientific Principles in Dissolution Methodology and Drug Testing Society

More information

In vitro - In vivo Correlation: From Theory to Applications

In vitro - In vivo Correlation: From Theory to Applications In vitro - In vivo Correlation: From Theory to Applications Jaber Emami Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran,

More information

Regulatory Requirements of Dissolution for Generic Drug Products

Regulatory Requirements of Dissolution for Generic Drug Products Regulatory Requirements of Dissolution for Generic Drug Products Om Anand, Ph.D. Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality - CDER, US-FDA International

More information

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables

More information

Public Assessment Report. Scientific discussion. Perindopril arginine Actavis (perindopril arginine) SE/H/1456/01-03/DC

Public Assessment Report. Scientific discussion. Perindopril arginine Actavis (perindopril arginine) SE/H/1456/01-03/DC Public Assessment Report Scientific discussion Perindopril arginine Actavis (perindopril arginine) SE/H/1456/01-03/DC This module reflects the scientific discussion for the approval of Perindopril arginine

More information

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies Case Study Title: Defining Process Design Space Case No. RMWG-07 GMP System Impacted: Introduction / Background

More information

Line extension of immediate release products

Line extension of immediate release products EMA/EGA Joint Workshop on the Impact of the Revised EMA Guideline on Modified Release Dosage Forms Line extension of immediate release products London, 30 th April 2014 Dr. Alfredo García Arieta Jefe de

More information

In silico tools to study food-drug interactions, an Industry Perspective

In silico tools to study food-drug interactions, an Industry Perspective Paris, April 4th, 2018 Physiologically Based PharmacoKinetic modeling (PBPK): A new Paradigm in Drug Development In silico tools to study food-drug interactions, an Industry Perspective Neil Parrott, Pharmaceutical

More information

Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products

Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products Paramjeet Kaur, Xiaojian Jiang, and Ethan Stier Division of Bioequivalence

More information

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats M. Maillard 1, D. Mordasini,D 1. Spaggiari 2, O. Phan 1, M. Ivarsson 3, R. Maj 3, L.A. Décosterd

More information

INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT

INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT HOW AN INTEGRATED DEVELOPMENT PLATFORM CAN PROVIDE END-TO-END VISIBILITY ACROSS PRE-FORMULATIONS AND FORMULATIONS DEVELOPMENT 1 A considerable amount and variety

More information

The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible?

The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible? The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible? Limin Zhang (Bristol-Myers Squibb Company) Andre Hermans (Merck & Co., Inc.) 2017 M-CERSI Workshop

More information

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets Muhammad Shahidul Islam 1, Kumar Bishwajit Sutradhar 2, Jakir Ahmed Chowdhury

More information

How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products

How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products James E. Polli jpolli@rx.umaryland.edu September 17, 2014 Perspective The societal promotion of generic products

More information

Biowaivers: BCS and IVIVC

Biowaivers: BCS and IVIVC Workshop in Celebration of 25 th Anniversary of the School of Pharmacy School of Pharmacy Faculty of Medicine The Chinese University of Hong Kong Biopharmaceutics of Modified Release Products and Challenging

More information

IN-VITRO AND IN-VIVO RELATIONSHIP AND INFLUENCE OF COVARIATES ON PHARMACOKINETICS OF URAPIDIL SUSTAINED RELEASE CAPSULES

IN-VITRO AND IN-VIVO RELATIONSHIP AND INFLUENCE OF COVARIATES ON PHARMACOKINETICS OF URAPIDIL SUSTAINED RELEASE CAPSULES Academic Sciences International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 6, Suppl 1, 014 IN-VITRO AND IN-VIVO RELATIONSHIP AND INFLUENCE OF COVARIATES ON PHARMACOKINETICS OF

More information

Effect of Various Sustained Release Polymers on Naproxen Sodium Release from Control Release Tablets

Effect of Various Sustained Release Polymers on Naproxen Sodium Release from Control Release Tablets International Journal of Pharmacy Teaching & Practices 3, Vol.4, Issue, 636-643. Effect of Various Sustained Polymers on Sodium from Control Tablets Md. Shamim Akhter *, Md. Amir Hossain, Emran Hossain

More information

Malleswari et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

Malleswari et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online) Comparative in-vitro dissolution study of five brands of Diclofenac sodium delayed release tablets in QbD environment V Malleswari Bai* 1, M Prasada Rao 1, M Chandana 1, K Naga Harini 1, B Naga Deepthi

More information

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION Pharmacopeial Forum Vol. 31(5)(Sept.-Oct. 2005) By : Mr. Seubpong Kumpusiri Mrs. Patima Maneesatid 26 May 2006 THE DISSOLUTION PROCEDURE: DEVELOPMENT

More information

The release of the drug substance from a solid dosage

The release of the drug substance from a solid dosage dx.doi.org/10.14227/dt210314p11 History and Evolution of the Dissolution Test Patrick J. Marroum Marroum Pharmaceutical Consulting, 9114 Blarney Stone Dr., Springield, VA 22152 e-mail: Marroum@prodigy.net

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION In format provided by Orchard et al. (SEPTEMBER 2011) Supplementary information S1 Sample MIABE file exemplifying data extracted from PMID: 20568778 Responsible Person or Role Contact Person Bryan K. S.

More information

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2 Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has

More information

The folowing four Rules-Of-Thumb summarize the more important aspects of electronic absorption:

The folowing four Rules-Of-Thumb summarize the more important aspects of electronic absorption: The folowing four Rules-Of-Thumb summarize the more important aspects of electronic absorption: 1. The amount of energy absorbed by an electron equals the quanta of energy of the photon absorbed. 2. Ground

More information

Unit V APPLICATIONS OF PHARMACOKINETICS

Unit V APPLICATIONS OF PHARMACOKINETICS Unit V APPLICATIONS OF PHARMACOKINETICS Presented by Mrs M. Sabareesh M.Pharm., Associate Professor Department of Pharmaceutics Krishna Teja Pharmacy college Subject; ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS(17SO3202)

More information

Development of Quality Control Method for Dissolution Analysis of Tapentadol and paracetamolin tablet

Development of Quality Control Method for Dissolution Analysis of Tapentadol and paracetamolin tablet Original Research Article Development of Quality Control Method for Dissolution Analysis of Tapentadol and paracetamolin tablet Krishna R Gupta 1,*, Kiran N. Kale 2 1 Professor, 2 Phd. Scholar, SKB College

More information

Biopharmaceutics Applications in Drug Development

Biopharmaceutics Applications in Drug Development Biopharmaceutics Applications in Drug Development Edited by Rajesh Krishna Merck & Co., Inc. Rahwav, NJ. USA and Lawrence Yu Center for Drug Evaluation & Research Rockville, MD, USA 4y Springer Contents

More information

A Novel Comparative Evaluation for the Quality of Oral Generic Drugs

A Novel Comparative Evaluation for the Quality of Oral Generic Drugs Regular Article Jpn. J. Pharm. Health Care Sci. 39(3) 156 165 (2013) A Novel Comparative Evaluation for the Quality of Oral Generic Drugs Masato Terashita, Kazuhiro Iguchi, Shigeyuki Usui and Kazuyuki

More information

In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria

In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria J Vector Borne Dis 45, March 2008, pp. 60 65 In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria C.O. Esimone a, F.B.C. Okoye b, B.U. Onah a, C.S. Nworu c & E.O. Omeje

More information

Comparative analysis of eight brands of sulfadoxinepyrimethamine

Comparative analysis of eight brands of sulfadoxinepyrimethamine Tropical Journal of Pharmaceutical Research, June 2003; 2 (1): 161-167 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights reserved. Available online at http://www.tjpr.freehosting.net

More information

The development of novel dissolution approaches

The development of novel dissolution approaches dx.doi.org/1.14227/dt22315p18 Development of a Glass-Bead Device for Dissolution Testing Marija Bogataj *, Greta Cof, and Aleš Mrhar Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, Ljubljana,

More information

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products

More information

Presentation Outline. Introduction Sources of Challenge for BE study

Presentation Outline. Introduction Sources of Challenge for BE study Presentation Outline Introduction Sources of Challenge for BE study Necessity of a BE Study? Study Design CRO Ethics Committee Regulatory Authority Sponsor (Personnel or Product) 1st MENA Regulatory Conference

More information

IMPROVING THE CORROSION RESISTANCE OF COMPONENTS MADE FROM STRUCTURAL STEELS

IMPROVING THE CORROSION RESISTANCE OF COMPONENTS MADE FROM STRUCTURAL STEELS UDK 669.14.18.298:62.193 ISSN 158-2949 Original scientific paper/izvirni znanstveni ~lanek MTAEC9 4(1)17(6) IMPROVING THE CORROSION RESISTANCE OF COMPONENTS MADE FROM STRUCTURAL STEELS POVE^ANJE KOROZIJSKE

More information

Carbon footprint. Špela Kern Umanotera, Slovenska fundacija za trajnostni razvoj E-pošta:

Carbon footprint. Špela Kern Umanotera, Slovenska fundacija za trajnostni razvoj E-pošta: Carbon footprint Špela Kern Umanotera, Slovenska fundacija za trajnostni razvoj E-pošta: [spela@umanotera.org] Abstract: Climate change is increasingly recognised as a major challenge. It is widely accepted

More information

DEVELOPMENT OF ALUMINIUM ALLOYS FOR AEROSOL CANS

DEVELOPMENT OF ALUMINIUM ALLOYS FOR AEROSOL CANS UDK 620.1:669.715:621.3.035.15 ISSN 1580-2949 Original scientific article/izvirni znanstveni ~lanek MTAEC9, 50(4)601(2016) J. TURK ET AL.: DEVELOPMENT OF ALUMINIUM ALLOYS FOR AEROSOL CANS 601 605 DEVELOPMENT

More information

Varnost nanomaterialov: povezava med njihovimi lastnostmi in učinki na okolje

Varnost nanomaterialov: povezava med njihovimi lastnostmi in učinki na okolje Varnost nanomaterialov: povezava med njihovimi lastnostmi in učinki na okolje Anita Jemec, Damjana Drobne Skupina za Nanobiologijo in Nanotoksikologijo, Biotehniška fakulteta, Oddelek za biologijo. www.bionanoteam.com

More information

Stability studies of the optimized oral metoclopramide hydrochloride tablet formulations prepared for IVIVC studies

Stability studies of the optimized oral metoclopramide hydrochloride tablet formulations prepared for IVIVC studies World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D BY Mohammed Mahmoud Academic Session 147-8 1 st Semester (Semester No 71)

More information

We embrace research and science, providing innovative products and integrated services to improve people s quality of life.

We embrace research and science, providing innovative products and integrated services to improve people s quality of life. Services Book 2016 Our DNA Philosophy We embrace research and science, providing innovative products and integrated services to improve people s quality of life. Vision We aspire to be one of the best

More information

Regulatory Assessment

Regulatory Assessment Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal

More information

THERMOMECHANICAL PROCESSING OF MICRO-ALLOYED STEEL

THERMOMECHANICAL PROCESSING OF MICRO-ALLOYED STEEL UDK 621.73:519.876.5 ISSN 1580-2949 Original scientific article/izvirni znanstveni ~lanek MTAEC9, 48(6)855(2014) P. PODANY, P. MARTINEK: THERMOMECHANICAL PROCESSING OF MICRO-ALLOYED STEEL THERMOMECHANICAL

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

More information

Dissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps

Dissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps Dissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps Xujin Lu 1, Jian-Hwa Han 2, Danna Mattocks 3 1 Analytical Science, DPST, Bristol-Myers Squibb Company 2 NCE-Analytical

More information

EFFECT OF TEMPERING ON THE ROOM-TEMPERATURE MECHANICAL PROPERTIES OF X20CrMoV121 AND P91 STEELS

EFFECT OF TEMPERING ON THE ROOM-TEMPERATURE MECHANICAL PROPERTIES OF X20CrMoV121 AND P91 STEELS UDK 669.14.018.44:621.785.72:620.17 ISSN 1580-2949 Original scientific article/izvirni znanstveni ~lanek MTAEC9, 46(5)459(2012) F. KAFEXHIU et al.: EFFECT OF TEMPERING ON THE ROOM-TEMPERATURE MECHANICAL

More information

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL DISSOLUTION This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control

More information

Preclinical Development Discovery to IND

Preclinical Development Discovery to IND Preclinical Development Discovery to IND Biobootcamp CBSA / Fitzsimons / FBBp / Holland & Hart Lauren C. Costantini, Ph.D. www.lccconsulting.net This Discussion Research and Development Product development

More information